Asia (Beijing)
UTC +8
Plenary session 1 (5.30 pm – 6.35 pm)
Real-world data, Covid-19 & biomarkers
- Heart failure in the real world in 2021 – Lars Lund (Sweden)
- Biomarkers in HF for diagnosis & treatment
guidance – Update 2021
– James Januzzi (USA) - Managing HF patients in COVID-19 times
– Pedro Schwartzmann (Brazil) - New devices to guide HF therapy
- Big data and AI for heart failure – What is on the horizon?
– Vidur Mahajan (India) - Panel discussion
Europe/Middle East (Athens)
UTC +3
Plenary session 3 (5.30 pm – 6.35 pm)
State of the art management of chronic HF
- RAASi/ARNi, MRAs and beta blockers
– Michael Böhm (Germany) - SGLT2 inhibitors overview 2021
– John McMurray (UK) - What do HF physicians needs to learn from CKD trials?
– Mark Petrie (UK) - SGLT2 inhibitors: focus on renal outcomes
– Milton Packer (USA) - Vericiguat, the new drug
– Burkert Pieske (Germany) - Panel discussion
Americas (New York)
UTC -4
Plenary session 5 (5.30 pm – 6.35 pm)
Update on advanced HF, assist devices and heart transplantation
- What about patients with LVEEF <20%
- Mechanical circulatory support (MCS)
– Tuvia Ben Gal (Israel) - Organising cardiac surgery and interventional care for HF
– Terrence M. Yau (Canada) - Destination LVAD
– Mandeep Mehra (USA) - Heart transplantation
– Anuradha Lala-Trindade (USA) - Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)
Plenary session 2 (7.40 pm – 8.45 pm)
The new HF guidelines: diagnostic & treatment algorithms
- Diagnostic algorithm for heart failure
– Justin Ezekowitz (USA) - Diagnostic approaches in HFpEF
– Justin Ezekowitz (USA) - HfrEF vs. HfmrEF vs. HfpEF – Similarities and differences
– Yuri Lopatin (Russia) - Treatment algorithm of HfrEF
– Marco Metra (Italy) - Treatment approaches in HfpEF
– Kavita Sharma (USA) - Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)
Plenary session 4 (7.40 pm – 8.45 pm)
Acute HF and the transition to ambulatory care
- Management of AHF – An overview
- Post MI heart failure
– Javed Butler (USA) - Inflammatory cardiomyopathy and viral myocarditis
– Biykem Bozkurt (USA) - Cardiogenic shock
– Yuhui Zhang (China) - Starting new drugs classes in hospital & organizing the discharge process
– Ovidiu Chioncel (Romania) - Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)
Plenary session 6 (7.40 pm – 8.45 pm)
Difficult problems in HF
- HF patients with a suspicion of amyloid
– Shelley Zieroth (Canada) - Heart failure in women – What is important to know?
– Karen Sliwa-Hahnle (South Africa) - Individualised management: the patient with ischemic heart failure
– Giuseppe Rosano (UK) - Management of heart failure in low resource settings
– Clara Ines Saldarriaga (Colombia) - The patient with cancer and cardio-toxic chemotherapy
– Alexander Lyon (UK) - Panel discussion
Asia (Beijing)
UTC +8
Plenary session 7 (5.30 pm – 6.35 pm)
Co-morbidities in HF affecting QoL and hard outcomes (part 1)
- What can the patients with poor QoL teach us?
– John Spertus (USA) - Sleep Apnea
– Andrew J. S. Coats (Australia) - Prevention of Atrial Fibrillation
– John Atherton (Australia) - Treatment of Atrial Fibrillation
– Paulus Kirchhof (Germany) - Managing obesity, frailty and cachexia
– Magdy Abdelhamid (Egypt) - Panel discussion
Europe/Middle East (Athens)
UTC +3
Plenary session 9 (5.30 pm – 6.35 pm)
Valvular heart disease in HF
- State of art for imaging for diagnosis of valvular disease and assessment of risk
– Fausto Pinto (Portugal) - Aortic valve disease
- Tricuspid disease
– William T. Abraham (USA) - Mitral valve disease – Focus on MitraClip
– Gregg Stone (USA) - Mitral valve disease – Focus on Carillon
– Horst Sievert (Germany) - Panel discussion
Americas (New York)
UTC -4
Plenary session 2 (5.30 pm – 6.35 pm)
The new HF guidelines: diagnostic & treatment algorithms
- Diagnostic algorithm for heart failure
– Justin Ezekowitz (USA) - Diagnostic approaches in HFpEF
– Justin Ezekowitz (USA) - HfrEF vs. HfmrEF vs. HfpEF – Similarities and differences
– Yuri Lopatin (Russia) - Treatment algorithm of HfrEF
– Marco Metra (Italy) - Treatment approaches in HfpEF
– Kavita Sharma (USA) - Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)
Plenary session 8 (7.40 pm – 8.45 pm)
Co-morbidities in HF affecting QoL and hard outcomes (part 2)
- CKD
– Gianluigi Savarese (Italy) - Diabetes in HF
– John Cleland (UK) - Diabetic Kidney Disease
– Gerasimos Filippatos (Greece) - Hyperkalemia
– Mikhail Kosiborod (USA) - ID with and without anaemia
– Stefan Anker (Germany) - Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)
Plenary session 1 (7.40 pm – 8.45 pm)
Real-world data, Covid-19 & biomarkers
- Heart failure in the real world in 2021 – Lars Lund (Sweden)
- Biomarkers in HF for diagnosis & treatment
guidance – Update 2021
– James Januzzi (USA) - Managing HF patients in COVID-19 times
– Pedro Schwartzmann (Brazil) - New devices to guide HF therapy
- Big data and AI for heart failure – What is on the horizon?
– Vidur Mahajan (India) - Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)
Plenary session 3 (7.40 pm – 8.45 pm)
State of the art management of chronic HF
- RAASi/ARNi, MRAs and beta blockers
– Michael Böhm (Germany) - SGLT2 inhibitors overview 2021
– John McMurray (UK) - What do HF physicians needs to learn from CKD trials?
– Mark Petrie (UK) - SGLT2 inhibitors: focus on renal outcomes
– Milton Packer (USA) - Vericiguat, the new drug
– Burkert Pieske (Germany) - Panel discussion
Asia (Beijing)
UTC +8
Plenary session 4 (5.30 pm – 6.35 pm)
Acute HF and the transition to ambulatory care
- Management of AHF – An overview
- Post MI heart failure
– Javed Butler (USA) - Inflammatory cardiomyopathy and viral myocarditis
– Biykem Bozkurt (USA) - Cardiogenic shock
– Yuhui Zhang (China) - Starting new drugs classes in hospital & organizing the discharge process
– Ovidiu Chioncel (Romania) - Panel discussion
Europe/Middle East (Athens)
UTC +3
Plenary session 6 (5.30 pm – 6.35 pm)
Difficult problems in HF
- HF patients with a suspicion of amyloid
– Shelley Zieroth (Canada) - Heart failure in women – What is important to know?
– Karen Sliwa-Hahnle (South Africa) - Individualised management: the patient with ischemic heart failure
– Giuseppe Rosano (UK) - Management of heart failure in low resource settings
– Clara Ines Saldarriaga (Colombia) - The patient with cancer and cardio-toxic chemotherapy
– Alexander Lyon (UK) - Panel discussion
Americas (New York)
UTC -4
Plenary session 8 (5.30 pm – 6.35 pm)
Co-morbidities in HF affecting QoL and hard outcomes (part 2)
- CKD
– Gianluigi Savarese (Italy) - Diabetes in HF
– John Cleland (UK) - Diabetic Kidney Disease
– Gerasimos Filippatos (Greece) - Hyperkalemia
– Mikhail Kosiborod (USA) - ID with and without anaemia
– Stefan Anker (Germany) - Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)
Plenary session 5 (7.40 pm – 8.45 pm)
Update on advanced HF, assist devices and heart transplantation
- What about patients with LVEEF <20%
- Mechanical circulatory support (MCS)
– Tuvia Ben Gal (Israel) - Organising cardiac surgery and interventional care for HF
– Terrence M. Yau (Canada) - Destination LVAD
– Mandeep Mehra (USA) - Heart transplantation
– Anuradha Lala-Trindade (USA) - Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)
Plenary session 7 (7.40 pm – 8.45 pm)
Co-morbidities in HF affecting QoL and hard outcomes (part 1)
- What can the patients with poor QoL teach us?
– John Spertus (USA) - Sleep Apnea
– Andrew J. S. Coats (Australia) - Prevention of Atrial Fibrillation
– John Atherton (Australia) - Treatment of Atrial Fibrillation
– Paulus Kirchhof (Germany) - Managing obesity, frailty and cachexia
– Magdy Abdelhamid (Egypt) - Panel discussion
Break (6.35 pm – 6.45 pm)
Plenary session 10 (6.45 pm – 7.30 pm)
The need for Global Cascade Guidelines: Key Points in the HF Guideline Approach
- HF Guidelines in China
– Jian Zhang (China) - HF Guidelines in India
– Vijay Chopra (India) - HF Guidelines in Japan
– Hiroyuki Tsutsui (Japan) - HF Guidelines in Russia
– Evgeny Shlyakhto (Russia) - HF Guidelines in Canada
– Shelley Zieroth (Canada) - HF Guidelines for Australia / New Zealand
– John Atherton (Australia) - HF Guidelines for South-East Asia
– David Sim (Singapore) - HF Guidelines for South America
– Jose Luis Navarro Estrada (Argentina) - Panel discussion
Break (7.30 pm – 7.40 pm)
Plenary session 9 (7.40 pm – 8.45 pm)
Valvular heart disease in HF
- State of art for imaging for diagnosis of valvular disease and assessment of risk
– Fausto Pinto (Portugal) - Aortic valve disease
- Tricuspid disease
– William T. Abraham (USA) - Mitral valve disease – Focus on MitraClip
– Gregg Stone (USA) - Mitral valve disease – Focus on Carillon
– Horst Sievert (Germany) - Panel discussion